| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 7403.9 | 7119.3 | 7589.4 |
| Other income | 151.2 | 210.9 | 268.9 |
| Total income | 7555.1 | 7330.2 | 7858.4 |
| Profit before exceptional items & tax | 1177.3 | 1081.9 | 1853.5 |
| Profit before tax | 1177.3 | 1081.9 | 1853.5 |
| Net profit | 851.5 | 785.5 | 1353.4 |
| Operating margin | 15.6% | 14.8% | 23.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -37.10% |
|---|---|
| Net profit, quarter on quarter | +8.40% |
| Revenue, year on year | -2.40% |
| Operating profit, year on year | -35.20% |
| Operating profit, quarter on quarter | +17.80% |
BSE results filing, NSE: CIPLA. Figures extracted from the filing.
Cipla Ltd: key numbers
- Share price
- ₹1,365.60
- Market cap
- ₹1,10,323 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 38.1×Sector 46.5×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.24%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Earnings Call Transcript: Key Takeaways
Cipla delivered record India revenue and margin expansion, masking high-stakes US product approval dependencies.
- Call
- Guides 20% growth
Cipla Employee Stock Options
Cipla granted 8,679 stock options and 27,140 ESARs to employees under its 2013 and 2021 schemes. Exercise price is INR 2 per option with graded vesting.
Cipla Management Change
Cipla's Board appointed Ms. Rashmi Joshi as additional Independent Director for 5 years. This strengthens the board's governance and financial oversight capabilities.
Cipla Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue INR 7,404 Cr (-2.4% YoY), EBITDA INR 1,388 Cr (18.7% margin), PAT INR 878 Cr (11.9%). Record quarterly India revenue; licensing deals in oncology biosimilars and ADCs.
Cipla Results Update
Cipla reported Q2FY27 consolidated revenue of ₹7,404 Cr and PAT of ₹878 Cr. EBITDA margin expanded 200 bps QoQ to 18.7%, with One-India growing 12% YoY.
Cipla Business Update
Cipla's subsidiary InvaGen received zero Form 483 observations in a routine USFDA cGMP inspection. The clean outcome confirms compliance at its US manufacturing facility.